Safety and efficacy of toripalimab plus concurrent chemoradiotherapy for locally advanced cervical cancer: a single-arm, phase Ib trial.

ABSTRACT:

Background

Although two pivotal phase III trials have evaluated the efficacy of adding immune-checkpoint inhibitors (ICIs) to concurrent chemoradiotherapy (CCRT) in locally advanced cervical cancer (LACC), discrepancies between the two studies highlight the need for further exploration of ICIs combined with CCRT in this setting.

Methods

Totally 30 patients with FIGO 2018 stage IB3-IVA cervical cancer were enrolled in this study. All patients underwent pelvic external beam radiotherapy (50.4 Gy in 28 fractions) followed by brachytherapy (30-36 Gy in 5-6 fractions), concurrent with cisplatin (40 mg/m² weekly) and toripalimab (240 mg every two weeks). The primary endpoint was adverse events, and secondary endpoints included the objective response rate (ORR) and progression-free

SUBMITTER: Jiang P 

PROVIDER: S-EPMC12522217 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature